September 27, 2016 11:50 PM ET


Company Overview of Tioga Pharmaceuticals, Inc.

Company Overview

Tioga Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of pruritus. It is involved in the Phase-2 clinical study of Asimadoline, an orally active highly selective kappa-opioid receptor specific agonist for the treatment of pruritus or itching associated with atopic dermatitis. The company was founded in 2005 and is based in San Diego, California.

4747 Executive Drive

Suite 700

San Diego, CA 92121

United States

Founded in 2005





Key Executives for Tioga Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 55
Chief Operating Officer
Chief Medical Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Tioga Pharmaceuticals, Inc. Key Developments

Tioga Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015

Tioga Pharmaceuticals, Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis

Tioga Pharmaceuticals announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States. Because of its mechanism of action, asimadoline has the potential to treat pruritus associated with a variety of conditions, including atopic dermatitis, psoriasis, end-stage renal disease, liver diseases such as cholestatic disease and primary biliary cirrhosis, malignancies, adverse drug effects, and certain orphan diseases. Chronic pruritus, which is defined as pruritus lasting six weeks or more, is associated with significant decrease in quality of life, including impact on sleep, anxiety, depression, and ability to work and lacks effective treatment options. Chronic pruritus is estimated to occur in approximately 20% of the general population (lifetime prevalence), with a very high incidence in certain dermatological and systemic conditions. The kappa-opioid system plays a pivotal role in the sensory transmission and processing of itch sensation from the skin to the brain. Animal models of chronic pruritus have demonstrated decreased kappa-opioid receptor activation or down regulation, coupled with increased mu-opioid receptor activation. Asimadoline has demonstrated efficacy in animal models of pruritus by significantly reducing the frequency of scratching induced by intra-dermally injected Substance P and significantly inhibiting scratching behavior induced by intra-dermally injected histamine or dinitrofluorobenzene.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tioga Pharmaceuticals, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at